Altimmune, Inc.
NASDAQ:ALTBiotechnology
+$0.08 today
- Market cap
- $297.72M
- Beta
- 0.23
- P/E (TTM)
- -3.7
- EPS (TTM)
- -$0.73
Volume 4.25M
Average 3.81M
ALT EPS (Basic)
Net income attributable to common shareholders divided by the weighted average basic shares outstanding.
Altimmune, Inc.NASDAQ: ALT
EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026
EPS (Basic) remains negative
Q1 FY2026 EPS (Basic) was -$0.18, compared with -$0.26 a year earlier. Trailing-twelve-month EPS (Basic) was -$0.93.
Context
- EPS (Basic) grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Basic) reaches the consensus estimate from 7 analysts of -$0.62 (+38.3%) for the fiscal year ending Dec 2026, a step up from the +25.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.18+33.3% QoQ
- Last fiscal yearDec 2025
- -$1+25.4% YoY
- LTMMar 2026
- -$0.93+26.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +30.8% | +48.7% | +17.9 pp |
| 1 year | +25.4% | +38.3% | +13.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Basic) history
USD · from the income statement
- Latest · FY2025
- (1.00) USD
- Year-over-year change
- +25.4%
| Period | Period end | EPS (Basic) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.00) | +25.4% |
| FY2024 | 2024-12-31 | (1.34) | +19.3% |
| FY2023 | 2023-12-31 | (1.66) | +8.3% |
| FY2022 | 2022-12-31 | (1.81) | +23.0% |
| FY2021 | 2021-12-31 | (2.35) | — |
EPS (Basic) vs competitors
How ALT compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +26.2% is the 6th highest of 9, against a peer median of +44.1%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $0.83 USD | +304.6% | — | |
| LTM Mar 2026 | -$0.58 USD | +90.9% | — | |
| LTM Mar 2026 | -$0.89 USD | +75.0% | — | |
| LTM Mar 2026 | -$0.93 USD | +26.2% | — | |
| FY2025 | -€1.82 EUR | +48.6% | — | |
| LTM Mar 2026 | -$2.74 USD | +39.6% | — | |
| LTM Jun 2026 | -$3.03 USD | +2.9% | — | |
| LTM Mar 2026 | -$3.13 USD | +25.8% | — | |
| LTM Mar 2026 | -$6.34 USD | -270.8% | — | |
| Peer median (excluding ALT) | — | +44.1% | — | |
Competitors are the stored peer set for ALT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.41M | (68K) | 426K | 20K | 41K |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 4.41M | (68K) | 426K | 20K | 41K |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 74.54M | 70.54M | 65.8M | 82.23M | 66.43M |
| Selling, General & Admin | 15.41M | 17.13M | 18.14M | 20.97M | 28.1M |
| Operating Expenses | 101.32M | 87.67M | 96.36M | 103.19M | 94.53M |
| Depreciation & Amortization | 551K | 493K | 477K | 238K | 112K |
| EBITDA | (96.53M) | (84.41M) | (87.94M) | (94.81M) | (87.03M) |
| EBITDA Margin | -2189.0% | 124130.9% | -20642.0% | -474060.0% | -212258.5% |
| Operating Income | (96.91M) | (87.74M) | (95.93M) | (103.17M) | (94.49M) |
| Operating Margin | -2197.6% | 129029.4% | -22518.5% | -515860.0% | -230461.0% |
| Interest Income | 203K | 2.87M | 7.35M | 8.07M | 7.54M |
| Interest Expense | 5K | 8K | 35K | 9K | 1.64M |
| Other Income / Expenses | (176K) | 2.83M | 7.48M | 8.11M | 5.72M |
| Income Before Tax | (97.09M) | (84.91M) | (88.45M) | (95.06M) | (88.77M) |
| Pre-Tax Margin | -2201.6% | 124867.6% | -20762.2% | -475295.0% | -216522.0% |
| Income Tax Expense | 0 | (197K) | 0 | 0 | (681K) |
| Net Income | (97.09M) | (84.71M) | (88.45M) | (95.06M) | (88.09M) |
| Net Margin | -2201.6% | 124577.9% | -20762.2% | -475295.0% | -214861.0% |
| EPS (Basic) | (2.35) | (1.81) | (1.66) | (1.34) | (1.00) |
| EPS (Diluted) | (2.35) | (1.81) | (1.66) | (1.34) | (1.00) |
| Weighted Avg Shares | 41.28M | 46.93M | 53.25M | 71M | 88.1M |
| Weighted Avg Shares (Diluted) | 41.28M | 46.93M | 53.25M | 71M | 88.1M |
Altimmune, Inc.
NASDAQ:ALT
Intrinsic Alpha fair value
Locked
Current Price
$1.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.